Key insights
- BMO Capital reiterated an Outperform rating on Eli Lilly (LLY) due to manageable post-marketing study requirements for Foundayo. Positive Phase 3 trial results for Jaypirca also support a bullish outlook. Upcoming earnings on April 30, 2026, will provide updates on Foundayo's launch, making LLY a stock to watch in the pharmaceutical sector. Overall, the news suggests continued positive momentum for LLY.
Investing.com - BMO Capital reiterated an Outperform rating and $1,300 price target on Eli Lilly shares (NYSE:LLY) on Tuesday, citing manageable post-marketing study requirements for the company’s recently approved Foundayo treatment. The pharmaceutical giant, with a market capitalization of $828 billion, is currently trading at $925, which InvestingPro data suggests is undervalued compared to its Fair Value—placing it among stocks on the Most Undervalued list.
The post-marketing study requirements outlined in the FDA’s April 1 approval letter for Foundayo appear manageable, according to BMO Capital. The firm does not expect these studies to have any meaningful impact on the competitive positioning of Lilly’s asset.
BMO Capital views the inclusion of several post-marketing studies as a reflection of conservatism from the FDA rather than an underlying risk to Lilly’s program. Investors continue to closely follow the product’s launch.
Eli Lilly is scheduled to report first-quarter earnings on April 30, 2026. Investors will be looking for updates on Foundayo’s launch progress during the earnings call. For deeper insights, InvestingPro offers a comprehensive Pro Research Report on LLY, one of 1,400+ US equities covered, transforming complex data into actionable intelligence.
The FDA approved Foundayo on April 1, 2026, triggering the post-marketing study requirements that are now under investor scrutiny.
In other recent news, Eli Lilly and Company announced that its Phase 3 BRUIN CLL-322 trial met its primary endpoint, demonstrating that Jaypirca, combined with venetoclax and rituximab, improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial enrolled 639 patients, and the treatment was administered for up to two years. Leerink Partners reiterated an Outperform rating on Eli Lilly stock following these positive trial results, maintaining a price target of $1,296. Additionally, RBC Capital reiterated an Outperform rating for Eli Lilly, projecting that sales of Zepbound and Mounjaro will exceed consensus estimates by 3% to 4% in the first quarter of 2026.
Eli Lilly’s newly FDA-approved oral GLP-1 medication, Foundayo, will be offered through Weight Watchers’ Med+ program, providing members with a once-daily, injection-free option for obesity or overweight treatment. Amazon Pharmacy also announced it would offer Foundayo with same-day delivery, increasing competition in the weight management medication market. These recent developments highlight Eli Lilly’s ongoing efforts to expand its product offerings and strengthen its position in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.